In a model involving human HCT116 xenograft transplantation into nude mice, those treated with rNAPc2, 5-FU, or bevacizumab (an anti-VEGF monoclonal antibody) exhibited tumor volume reduction compared to untreated mice. The gene discussed is VEGFA; the disease is neoplasm.